Last updated on July 2020

Study to Evaluate Safety Tolerability and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

Brief description of study

This is a 3-part, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of XNW4107 given as intravenous (IV) infusion in healthy male subjects. In part 1, subjects will receive a single dose of XNW4107. In part 2, subjects will receive XNW4107 for 7 days. In Part 3, subjects will receive XNW4107 in combination with imipenem/cilastatin for 14 days.

Clinical Study Identifier: NCT04482569

Find a site near you

Start Over

Pharmaron CPC

Baltimore, MD United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.